Biotech Distilled
Substack ↗ Subscribe
Subscribe Substack ↗ About

Home › Companies › EVMN

Evommune

EVMN Lead: Phase 2 6 Biotech Distilled articles ↓ 34 filings & releases ↓ Cash $60.0M (Jun 30, 2026) ↓ 6 verdicts ↓ 3 timing quotes ↓
DermatologyImmunologyNeurology ProteinSmall Molecule

Market cap $241M 36.3M shares (10-Q, Aug 4, 2026) × $6.65 close Nov 6, 2026

Most recent annual filing: 2026-03-15

Catalyst timeline

5 trackedQuarter catalyst calendar →
  1. EVO301 corporate update2H 2026EVO301 corporate update, 2H 2026, routine
  2. EVO756 topline2027EVO756 topline, 2027, major
  3. EVO570 corporate update~Jan 2027EVO570 corporate update, ~Jan 2027, routine
  4. EVO301 Ph2b startMid-2027EVO301 Ph2b start, Mid-2027, routine
  5. EVO646 Ph1 readoutLate 2027EVO646 Ph1 readout, Late 2027, notable

Bar width shows how precise the guidance is — a pin is a stated date, a wide band a six-month window. Deeper blue means more of the thesis rides on the event; it is not a view on the stock.

Pipeline (6 active programs)

Technology platforms

SAFAbody · AprilBio Co., Ltd.

SAFA (Anti-Serum Albumin Fab-Associated) fusion protein platform enabling half-life extension via FcRn-mediated HSA recycling and efficient tissue distribution; used to engineer long-acting IL-18BP therapeutics for inflammatory diseases including atopic dermatitis

Targets: IL-18BP, HSA

Discontinued (2)

Capital (as filed)

Cash
$60.0M cash and cash equivalents · Jun 30, 2026 (10-Q)
Short-term investments
$141M Jun 30, 2026
Long-term investments
$87.2M Jun 30, 2026
Operating cash flow
−$20.3M quarter Mar 31, 2026 → Jun 30, 2026, year-to-date difference (10-Q)
As stated in coverage
$262M cash, runway second half of 2029 per the update of Nov 4, 2026 — the company's own words as read there, not the filed figure

Offering documents (5)

Cash, investments and operating cash flow are the company's own XBRL facts as filed with the SEC, each shown with its period end and tag. As-stated figures come from the company's own words as read in Biotech Distilled coverage, dated, and routinely count securities and planned financing that a balance sheet does not. Offering rows are the SEC cover pages as filed. Not investment advice. Figures as of Nov 7, 2026.

Biotech Distilled coverage (6)

Articles open on Substack. Some are subscriber-only; those marked ★ Distilled Pro are for Distilled Pro members.

Verdict history (6 calls)

Every verdict Biotech Distilled has published on Evommune, oldest first — the full history, never a selection. How calls are scored: the track record.

  1. 2026-05-22 Watch Evommune (EVMN) — Scientific Deep Dive for EVO756, EVO301 and Pipeline Products Strong science and smart-money cap table, but licensed-and-leveraged economics and a brutal CSU comparator bar (barzolvolimab 51% UAS7=0) warrant watching rather than buying ahead of the binary June readout.
  2. 2026-06-30 Avoid UPDATE: Evommune (EVMN) — The CSU Shot Misses EVO756 missed the CSU Phase 2b primary endpoint at every dose, zeroing the largest SOTP line item; the mechanism failed its cleanest randomized test and read-across to AD is now negative, leaving only thinner, longer-dated options.
  3. 2026-08-07 Avoid UPDATE: Evommune (EVMN) - The Clock Moves Up to September AD Phase 2b topline moved to September 2026 but the dose ceiling keeps falling (100 mg in migraine vs 150 mg in failed CSU), burn accelerated to ~$32M/quarter, and the mechanism still carries a negative prior from its cleanest randomized test.
  4. 2026-09-09 Avoid UPDATE: Evommune (EVMN) - The Second Shot Misses Too EVO756 missed the AD Phase 2b primary and every secondary at every dose, making two clean Phase 2b failures across all dose arms; only a low-probability migraine lottery ticket and EVO301 (a year from data) remain.
  5. 2026-10-01 Watch UPDATE: Evommune (EVMN) - The Last Shot Standing Shows Its Numbers EVO301 posted a statistically clean placebo-controlled Phase 2a signal (55% vs 22% EASI reduction, p<0.01) with consistent secondaries and clean safety, while the stock trades near cash per share, making it worth tracking again.
  6. 2026-11-05 Watch UPDATE: Evommune (EVMN) - A Third Shot, Paid for in Shares In-licensing EVO570 (VAV1 molecular glue degrader) for $30M upfront broadens the pipeline cheaply relative to the Novartis comparable, but the asset is preclinical with no human efficacy data and the 17% dilution at the stock's historic low keeps the stance at watch.

Every verdict Biotech Distilled has published on this company, in order, with the post it came from — the full history, never a selection. Position figures are the same ones shown on /track-record, computed by the same method. Editorial opinion, not investment advice.

Timing, in the company's words (3 quotes from 3 filings)

Sentences quoted verbatim from the company's SEC filings, newest filing first. Each sits under the filing it appeared in; the "matched to" tag names the calendar row it was read for.

Timing sentences quoted from the company's own SEC filings, each under the filing it appeared in. The 'matched to' tag is the calendar row the sentence was read for; the filing is the source. Not investment advice.

Filings & releases (34)

SEC filings from EDGAR and press releases captured from the company's investor-relations site, newest first. Releases captured from Jul 30, 2026; filings from March 2026. Summaries come from the BD update that read the document; "BD extracted" counts point at the pipeline table above. All companies →

8 more filings (13G holder notices, S-8, proxy material, SEC correspondence …)